Introduction
Sam68, the Src-Associated substrate during Mitosis of 68 kDa, is a member of the STAR (Signal Transduction Activator of RNA) family of RNA-binding proteins proposed to link signaling cascades to RNA metabolism (Vernet and Artzt, 1997; Lukong and Richard, 2003) . These proteins share at least three functional motifs including a K (hnRNP K) homology (KH) RNAbinding domain embedded in a larger domain termed the GSG (GRP33, Sam68, GLD-1) or the STAR domain, proline-rich SH3 (Src homology domain 3)-binding and SH2-interacting tyrosine-rich motifs (Lukong and Richard, 2003) . Sam68 is a substrate of breast tumor kinase (BRK; Derry et al., 2000) , a kinase overexpressed in about 60% of breast tumors (Kamalati et al., 1996) . The tyrosine phosphorylation of Sam68 may be a marker for certain cancers where tyrosine kinases are induced. Indeed, we have shown that Sam68 is a substrate downstream of the epithelial growth factor (EGF; Lukong et al., 2005) and Sam68 tyrosine phosphorylation is elevated in human breast tumors tissues and cell lines (Babic et al., 2004; Lukong et al., 2005) . Consistent with these findings is the elevated expression of Sam68 observed in prostate cancer tissues (Busa et al., 2007) . These findings suggest that tyrosine phosphorylation of Sam68 and its expression are required for tumorigenesis. Conversely, the reduced expression of Sam68 in NIH3T3 cells using a gene trap strategy and antisense-induced neoplastic transformation suggests Sam68 may have tumor suppressor properties (Liu et al., 2000) . However, the Sam68 À/À mice live to old age (B2 years) and were not prone to tumor formation, suggesting that Sam68 is not a tumor suppressor in vivo .
Results

Sam68
À/À mice have defects in breast and uterine development Herein, we investigated whether the absence of Sam68 prevented or accelerated tumorigenesis in vivo, and we employed the mammary-targeted polyoma middle T antigen (MMTV-PyMT) mouse model because PyMT utilizes Src for signaling and induces rapid breast tumors that resemble human breast cancers (Lin et al., 2003) . Whole-mount analysis and hematoxylin/eosin staining of sections of the fourth inguinal mammary glands of 6-and 12-week-old virgin females from Sam68
and Sam68 À/À mice were performed to examine mammary development (Figure 1 ). Both wildtype and heterozygous Sam68 mice displayed normal and comparable ductal outgrowth ( Figure 1a , top and middle panels) consistent with Sam68 þ /À females bearing Figure 1 Sam68 À/À mice display a mammary gland defect. (a) Whole-mount analysis of mammary glands from Sam68 mice is shown (n>4). Scale bar 2 mm and the lymph node (LN) is depicted. (b) Terminal-end buds and number of branchings were counted and expressed as the mean7s.d. of the mean. *P-valueo0.01. (c) Histological examination by hematoxylin/eosin of 6-and 12-week-old mammary glands from Sam68 þ / þ , Sam68 þ /À and Sam68 À/À mice. Scale bar, 100 mm.
Sam68 modulates signaling in mammary tumorigenesis S Richard et al normal litters and lactating normally (data not shown). In contrast, Sam68 À/À mice had a striking defect in the development of the ductal outgrowth observed in 6-week-old mice, and this difference was less obvious and partially recovered in 12-week-old mice ( Figure 1a , lower panels). The 6-week-old Sam68 À/À mice had approximately three times less terminal end buds compared with Sam68 þ / þ and Sam68 þ /À littermate mice (Figure 1b) . Adult virgin female mice of 12-week-old mice had fully developed ductal trees; however, the ductal outgrowth density was lower in whole mounts of Sam68 À/À mice compared to Sam68 þ / þ and Sam68 þ /À mice, as assessed by counting the number of branches in a given area (Figure 1b ). Histological analysis of the mammary glands showed a normal epithelium with fewer cross-sections of mammary ducts in the 6-weekold Sam68 À/À female mice compared to littermate controls or 12-week-old Sam68 À/À mice, as predicted with the reduced ductal outgrowth in 6-week-old Sam68 À/À mice ( Figure 1c ). We next investigated the gross morphological analysis of the ovaries and uteri derived from 6-and 12-week-old Sam68 mice. The gross morphology of the uteri from 6-week-old Sam68 À/À females appeared atrophic and less developed compared with Sam68 þ / þ and Sam68 þ /À mice; however, this difference was not visible in 12-week-old Sam68
À/À mice ( Figure 2a ). Histological analysis revealed a normal endometrium with a wellorganized outer layer of smooth muscle in Sam68 mice (Figure 2b ). However, cross-sectioning of the uteri revealed that the uteri of Sam68 À/À mice are smaller than those observed in Sam68 þ / þ and Sam68 þ /À mice ( Figure 2b ). Histologically, no discernable difference is observed between ovaries from 6-and 12-week-old Sam68 mice (Figure 2c ). Primary follicles and corpora lutea are present, consistent with the fact that Sam68 À/À female mice are fertile and give birth to reduced litter sizes . Taken together, our observations show that Sam68 deficiency delays the normal development of the uterus.
Sam68 haploinsufficiency delays mammary tumor onset and multiplicity in PyMT transgenic mice Mammary tumorigenesis phenotypically similar to human breast cancers has been induced in mice by targeted overexpression of oncogenes including the PyMT driven by the MMTV promoter (Lin et al., 2003) . PyMT leads to the activation of signaling cascades that parallel the activation of Neu/Erb-B2 in human mammary carcinomas (Muller et al., 1988; Guy et al., 1992; Lucchini et al., 1992) . All female virgin MMTV-PyMT transgenic mice rapidly develop multifocal mammary adenocarcinomas with 100% penetrance and short latency. Other studies have indicated that PyMT signals through Src in potentiating mammary tumor development (Courtneidge et al., 1991; Muthuswamy and Muller, 1994) . Sam68 itself is an Src substrate and probably plays an adapter role downstream of the Src pathway (Lukong and Richard, 2003) . To examine whether Sam68 is a signaling requirement for PyMT, we employed the MMTV-PyMT transgenic as a model to assess the effect of Sam68 haploinsufficiency in mammary tumor development and tumor incidence. Sam68 À/À mice displayed an overt mammary defect (Figure 1) , and, therefore, could not be used in these studies. Therefore, Sam68 þ /À mice were bred with MMTV-PyMT transgenic mice and 6-week-old female offspring palpated twice a week in the mammary glands for the development of tumors. The animals were killed as soon as one tumor reached 1.5 cm 3 in size and the data expressed using a KaplanMeier analysis. The absence of one allele of Sam68 in PyMT/Sam68 þ /À mice (n ¼ 14) delayed tumor development to 122 days as opposed to 80 days observed in PyMT/Sam68 þ / þ (Figure 3a ). The tumor onset in wild-type background was approximately 11 weeks, consistent with a C57BL6/FVB mice mixed background (Cheng et al., 1998) . To assess tumor multiplicity, cohorts of PyMT/Sam68
þ /À (n ¼ 10) female mice were analysed. We also noted a marked decrease in tumor multiplicity in PyMT/Sam68 þ /À mice compared to PyMT/Sam68
mice, with an average of 2.5 and 4.92 tumors per mouse, respectively ( Figure 3b ). These data indicate that Sam68 haploinsufficiency results in both increased tumor latency and decreased tumor multiplicity in the MMTV-driven PyMT mice. These findings suggest that Sam68 is required for PyMT-induced mammary tumorigenesis.
Src and FAK are activated in PyMT/Sam68 þ /À tumors PyMT-mediated tumorigenesis involves recruitment and/or activation of several signaling molecules including c-Src, phosphatidylinositol 3-kinase (PI-3K), Akt and Ras (Andrechek and Muller, 2000) . As an intracellular target of Src, Sam68 itself may be a downstream effector of the PyMT pathway. To determine whether the decreased tumorigenicity in PyMT/ Sam68 þ /À mice is associated with altered expression and/or activation of selected PyMT-coupled signaling molecules, we performed immunoblotting on tumor tissues from PyMT/Sam68 þ / þ and PyMT/Sam68 mice. We examined at least six tumors for each genotype and representative immunoblots are shown demonstrating that PyMT/Sam68 þ /À mice did not affect the constitutive expression or activation of PI-3K and Akt (Figure 4) . Interestingly, the phosphorylation of Src (pY416), FAK (pY397, pY576 and pY577) was elevated in all PyMT/Sam68 þ /À tumor lysates compared to PyMT/Sam68 þ / þ tumor lysates (Figure 4) . FAKY397 is the autophosphorylation site that drives the initial activation of the kinase, while Y576 and Y577 are preferentially phosphorylated by Src, resulting in Sam68 modulates signaling in mammary tumorigenesis S Richard et al maximal FAK activation (Cohen and Guan, 2005) . b-Actin and PRMT1 immunoblots were used as controls for equal loading. These findings show that the reduction of Sam68 in an in vivo setting leads to the increased presence of active marks on Src (pY416) and FAK (pY397, pY576, pY577) tyrosine kinases.
Sam68 knockdown limits PyMT-induced tumor growth
Our findings that haploinsufficiency of Sam68 impedes mammary tumor onset and tumor multiplicity in PyMT mice prompted us to examine whether this phenotype is cell autonomous. The Db7 cell line is a serially transplantable, MMTV-PyMT Y315F/Y322F mammary Sam68 modulates signaling in mammary tumorigenesis S Richard et al adenocarcinoma-derived cell line (Borowsky et al., 2005) . Using short-hairpin RNA that targets mouse Sam68 (Sam68sh), we achieved over 90% knockdown of Sam68 expression, as evidenced by immunoblotting analysis with b-actin and c-Src as loading controls (Figure 5a ). Next, we injected 10 6 cells of either Db7-pSUPER or Db7-Sam68sh cells into the mammary fat pad of athymic mice (n>11). After 3 weeks, tumors were isolated and weighed. We observed an B35% decrease in tumor size and weight generated from Db7-Sam68sh-injected mice, as compared to the Db7-pSUPER control (Figure 5b ). Immunoblot analysis of the lysates from the Db7 tumors confirmed that Sam68 knockdown was maintained during the development of the tumors except for one (Figure 5c, lane 7) . PRMT1 was used as a loading control in this experiment. These results indicate that depletion of Sam68 in Db7 cells limits tumor burden in mice, and demonstrate that Sam68 functions in cell autonomous manner to regulate PyMT-induced mammary tumorigenesis.
Sam68 knockdown results in decreased lung metastasis
We next extended our studies to investigate the involvement of Sam68 in PyMT-induced metastasis. To this end, we used Met-1 cells known to have an elevated metastatic potential (Borowsky et al., 2005) . We thus generated control (pSUPER) and Sam68 knockdown (Sam68sh) cells in Met-1 cells. A knockdown of B90% was obtained using b-actin and PRMT5 as loading controls (Figure 6a ). The levels of PyMT protein remained equivalent between pSUPER and Sam68sh Met-1 cells and the addition of the proteasome inhibitor (MG132) caused the appearance of a slower migrating form of PyMT, but there was no difference between pSUPER and Sam68sh cells (Figure 6a ). The findings suggest that a slower migrating PyMT protein may represent ubiquitylated PyMT. To examine whether the reduced levels of Sam68 affect the metastatic potential of the Met-1 cells, we performed an in vivo metastatic analysis. Athymic mice were hence injected i.v. with pSUPER Met-1 cells (n ¼ 12) or 
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Sam68sh Met-1 cells (n ¼ 12) and 40 days later, the lungs were harvested and foci counted and scored under a stereomicroscope. The number of foci in the lungs of mice injected with the Sam68sh Met-1 cells was significantly reduced by B5-fold compared to wild-type Met-1 and pSUPER Met-1 cells (Figure 6b) . A decrease in metastatic potential is often correlated with a defect in cell migration and haptotactic migration was analysed using a Transwell chamber assay. Sam68sh Met-1 showed a significantly impaired migration compared to the parental Met-1 cell line and the pSUPER Met-1 cells (Figure 6c ). These findings suggest that the lack of metastasis observed in vivo is due to a lack in cell migration in Sam68-deficient Met-1 cells.
Discussion
Sam68
À/À female mice displayed mammary gland development and uterine atrophy at prepuberal age where estrogen, growth hormone, growth factors (IGF-1) and corticoids play a major role (Fendrick et al., 1998; Hovey et al., 2002) . The phenotype observed in the Sam68 À/À mice could be explained by a lack of estrogen at the prepuberal age. However, measurement of the plasma estrogen levels revealed that estrogen levels were significantly elevated (Po0.01 Sam68 À/À versus Sam68 þ / þ ; n ¼ 4) in 6-week-old Sam68 À/À mice (29.7374.71 pg/ ml) compared to Sam68 þ / þ (17.5772.28 pg/ml) and Sam68 þ /À (23.1875.64 pg/ml) mice. Estrogen levels remained elevated in 4-month-old Sam68 À/À female mice but the difference was not statistically significant . These observations are counterintuitive but may reflect a lack of estrogen responsiveness as observed in estrogen receptor-a null mice that have increased plasma estrogen levels and display mammary gland and uterine development defects (Lubahn et al., 1993; Schomberg et al., 1999) . Future experiments are required to determine the hormonal responsiveness of Sam68 À/À mice. c-Src null mice (Soriano et al., 1991) known to regulate ERa expression also display defects in mammary glands, ovarian and uterine development (Kim et al., 2005) , demonstrating that Src and Sam68 null mice have similar target tissues. Our findings suggest that in humans a delay in the onset The reduced levels of PyMT expression in tumor extracts from PyMT/Sam68 þ /À may explain the reduced mammary gland tumorigenesis observed. However, reduced PyMT expression was not observed in PyMT cell lines harboring Sam68sh, and yet tumor formation and metastasis in nude mice was significantly delayed. Collectively, these findings suggest that Sam68 is likely a signaling requirement for PyMT-mediated tumorigenesis and metastasis. It is possible that the increased Src activity observed in tumor extracts from PyMT/ Sam68 þ /À mice necessitates an in vivo tumor environment to promote the ubiquitylation and degradation of PyMT by the protesome pathway. The fact that we observed slower migrating PyMT species with the proteasome inhibitor MG132 makes this a viable possibility. It is well documented that Src family kinases promote the ubiquitylation and proteasomal degradation of certain of their substrates (Fujita et al., 2002; Bao et al., 2003) . The fact that the protein levels of PyMT did not change between pSUPER and Sam68sh in Met-1 cells suggests that PyMT is not a direct protein or RNA target of Sam68.
How is it possible to have activated Src and FAK and observe reduced tumorigenesis and metastasis? Although c-Src is required for efficient mammary tumorigenesis, multifocal mammary tumors and metastasis (Guy et al., 1994) , mammary epithelial expression of an activated c-Src oncogene in transgenic mice induces mammary hyperplasia but not multifocal mammary tumors in PyMT strains (Webster et al., 1998 ). It appears from our studies therefore that active Src alone is not sufficient for tumor induction, and may require Sam68 for a comprehensive induction of tumorigenesis. Thus, in the case of PyMT/Sam68 þ /À tumors in the present study, Src activation alone may not be sufficient to induce rapid tumor progression.
How can the haploinsufficiency of Sam68 result in active Src kinase activity in a PyMT expressing cell? Sam68 is hypothesized to play an adapter role in a multitude of signaling pathways since it have been shown to form SH2-and/or SH3-domain interactions with various signaling molecules including GRB2 Sam68 modulates signaling in mammary tumorigenesis S Richard et al (Lukong and Richard, 2003) . Several studies have shown that disruption of certain genes leads to abnormal mammary development and tumorigenesis (Andrechek and Muller, 2000) . For example, the haploinsufficiency of GRB2 delays PyMT-induced tumor progression (Cheng et al., 1998) , suggesting that Sam68 may indeed fulfill a signaling requirement for PyMT-mediated tumorigenesis. As Sam68 is a substrate and interacting partner of Src, it may function in a similar fashion as was reported for RACK1 (Mamidipudi et al., 2007) , and it remains to be examined whether Sam68 RNA-binding activity and that of the splicing regulator SRm160 are required for this function and whether CD44 alternative splicing contributes to the observed phenotype (Matter et al., 2002; Cheng and Sharp, 2006) . The mechanism for Src activation and inhibition of PyMT expression in PyMT/Sam68 þ /À tumors is unclear. But it seems to necessitate an in vivo tumor environment since asynchronously growing PyMT-transformed cells demonstrate normal levels of PyMT ( Figure 6 ). How do all these events account for the delay in the onset of mammary tumors in the PyMT/Sam68 þ /À ? The middle 'T' has been tightly associated with transforming capabilities, and is able to engage both the PI-3 kinase and MAPK cascades (Dilworth, 2002) . We speculate first that the increase activation of Src is not paralleled with an activation of the survival pathways (AKT). Second, as a modulator of mesenchymal cell differentiation , Sam68 may be involved in the epithelial-mesenchymal transition, characterized by altered cellular morphology, loss of cell adhesion and gain of migratory ability (Barbera et al., 2004; Larue and Bellacosa, 2005; Christiansen and Rajasekaran, 2006) .
Materials and methods
Mouse models
The genotyping of PyMT transgenic mice was preformed by PCR with the following primers: forward, 5 0 -GGAAGCAAG TACTTCACAAGGG-3 0 ; reverse, 5 0 -GGAAAGTCACTAG GAGCAGGG-3 0 . Once a tumor reached a volume of 1.5 cm 3 , assessed by a caliper, the mice were killed. Mammary, ovarian and uterine tissues were fixed in 10%-buffered formalin and embedded in paraffin for sectioning. The sections were then stained with hematoxylin and eosin staining by the Department of Pathology at the Jewish General Hospital (Montreal, Quebec, Canada).
Cell culture
For mammary fat pad injection, inguinal (n ¼ 4) mammary pads of athymic mice were injected with 10 6 Db7pSUPER or Db7Sam68sh cells and tumors weighed after 4 weeks. For the metastasis analysis, 2 Â 10 5 pSUPERMet-1 or Sam68shMet-1 cells were injected i.v. in female athymic mice, and after 40 days lung foci assessed. Haptotactic migration was performed with the Corning Transwell with a serum gradient and the cells were permitted to migrate overnight, stained with crystal violet and counted. RNA interference for Sam68sh was performed as described previously .
Antibodies and estrogen levels Antibodies recognizing Sam68, PRMT1, PRMT5, p85 subunit of PI-3 kinase, phospho-AKT, AKT, phospho-Src (Y416) were from Upstate/Millipore (Billerica, MA, USA). The bactin antibody was purchased from Sigma (St Louis, MO, USA) and the phospho-FAK (Y576; Y577; Y397) and phospho-paxillin were from Biosource (Camarillo, CA, USA). The estrogen levels in plasma were measured in duplicate from four mice of each genotype using Estradiol Coat-A-Count from Diagnostic Products Corporation (Los Angeles, CA, USA).
